Rolling Review is a process used by the US Food and Drug Administration (FDA) to expedite the review of new drug applications.

On Dec 2, 2023, results from a Penpulimab-based neoadjuvant/adjuvant therapy trial for resectable advanced non-small cell lung cancer were presented at ESMO_ASIA 2023.

The term 'postmarketing requirement' (PMR) refers to mandatory post-approval studies or trials, including those mandated by the FDAAA, 21 CFR part 314 subpart H, 21 CFR part 601 subpart E, the Pediatric Research Equity Act, and the Animal Efficacy Rule.

Halia Therapeutics initiated treatment with HT-6184, a novel NLRP3 inhibitor, in an initial participant for its early-stage Phase 2a study aimed at addressing lower-risk types of myelodysplastic conditions.

Serious risk means a risk of a serious adverse drug experience.

Thrombin inhibitors are drugs that specifically target and inhibit thrombin, a key enzyme in blood clotting.

Guillain-Barré syndrome (GBS) is a rare disorder in which a person’s own immune system damages the nerve cells, causing muscle weakness and sometimes paralysis.

Agomab Initiates First-Stage Research Trial on AGMB-447 with Healthy Participants and Individuals Diagnosed with Idiopathic Pulmonary Fibrosis.

Protein amidation is the process through which a carboxyl group is converted into an amide group.

The development of STAT3 inhibitors will be increasingly valued in the future, and targeting the STAT3 signaling pathway has become a promising strategy for the treatment of various cancers.

The emergence of oligonucleotide drugs makes it possible to actively design drug sequences to target and silence disease genes.

At the 2023 ESMO_ASIA , the latest clinical results of Cadonilimab were presented, demonstrating its potential therapeutic effect on HCC and laying a solid foundation for the next wave of research.